Based on a small cohort study where 4 of 6 acral melanomas responded to second-line Lenvatinib plus ICI [75] and an early clinical study where Anlotinib, another dual FGFR/VEGFR inhibitor, provided a significant survival benefit when used with ICIs [76], targeting AM with FGFR/VEGFR inhibitors are expected to provide a survival benefit for patients. The gene discussed is KDR; the disease is melanoma.